6 quiz questions available for this topicTake Quiz
Palliative care - cough
💡
Exam Tips
- In palliative OSCEs, state early that investigations should be proportionate to prognosis, likely benefit, and patient preference.
- Use cough quality diagnostically: 'bovine' suggests recurrent laryngeal nerve palsy; 'brassy' suggests central airway/tracheal compression.
- Always ask about timing with meals and swallowing to detect aspiration-related cough.
- If sputum is purulent or there is fever, consider treatable infection even in advanced cancer.
- When proposing opioids for cough, mention anticipatory side-effect management (constipation prophylaxis, sedation monitoring, renal dose caution).
- Image revision point: review textbook chest X-ray figures of pleural effusion (meniscus, blunted costophrenic angle) and lobar collapse patterns to strengthen viva interpretation.
Definition
Cough in palliative care is a distressing protective reflex caused by stimulation of airway vagal receptors, but in advanced illness it is often multifactorial and can become non-beneficial. In people with cancer, it commonly reflects thoracic disease (for example endobronchial tumour, pleural involvement, lymphangitis) or treatment/complication effects, and should be assessed in relation to prognosis, patient goals, and reversibility.
Pathophysiology
The cough reflex begins with mechanical/chemical stimulation of irritant receptors in the larynx, trachea, and bronchi (via vagal afferents), with central integration in the brainstem and coordinated expiratory muscle activation. In palliative patients, tumour-related airway narrowing, pleural/parenchymal infiltration, mucus hypersecretion, aspiration, infection, reflux, and treatment-related lung injury increase receptor activation and cough reflex sensitivity. Repeated inflammation can produce cough hypersensitivity, while weakness, poor hydration, impaired mucociliary clearance, and vocal cord dysfunction make cough ineffective, leading to secretion retention and further cough-dyspnoea cycles.
Risk Factors
- Primary lung, pleural, mediastinal, or upper airway malignancy
- Thoracic metastatic disease (including lymphangitis carcinomatosa)
- Endobronchial lesions or major airway compression
- Pleural effusion or pericardial effusion
- Recent or prior thoracic radiotherapy (pneumonitis/fibrosis)
- Chemotherapy-related interstitial/fibrotic lung toxicity
- Aspiration risk (bulbar weakness, neuromuscular incoordination, oesophageal/pharyngeal disease)
- Respiratory infection in immunocompromised or frail patients
- Comorbid asthma, COPD, heart failure, GERD, bronchiectasis
- Drug triggers such as ACE inhibitors, beta-blockers, nitrofurantoin
- Smoking history and reduced mucociliary clearance
- Poor performance status with weak respiratory/abdominal musculature
Clinical Features
Symptoms
- Dry persistent cough over weeks (often tumour-related)
- Barking short-lived dry cough (pharyngitis/tracheobronchitis/early pneumonia pattern)
- Hoarse croup-like cough (laryngeal inflammation)
- Low-volume 'bovine' cough suggesting recurrent laryngeal nerve palsy
- Metallic 'brassy' cough suggesting tracheal compression
- Loose or productive cough with moving airway secretions
- Cough with meals or after swallowing suggesting aspiration
- Wheezy cough with airflow obstruction
- Associated sputum change: purulent, thick yellow/green, frothy, or blood-stained
- Associated dyspnoea, chest discomfort, sleep disturbance, fatigue, social embarrassment, urinary stress incontinence
Signs
- Tachypnoea or increased work of breathing
- Reduced chest expansion (collapse or pleural effusion)
- Dull percussion (collapse) or stony dull percussion (pleural effusion)
- Bronchial breath sounds over consolidation
- Wheeze or stridor (endobronchial obstruction/tracheal compression/SVC-related congestion)
- Crepitations from infection, fluid overload, or parenchymal involvement
- Weak ineffective cough with poor secretion clearance
- Signs of aspiration, cachexia, dehydration, or reduced consciousness
Investigations
Focused clinical assessment (history + chest exam + cough effectiveness):Character clues to cause (e. g, brassy cough with tracheal compression, post-prandial cough with aspiration, purulent sputum with infection)
Pulse oximetry and basic observations:Hypoxia, tachypnoea, fever, haemodynamic instability guiding urgency
Chest X-ray:Pleural effusion, lobar collapse/consolidation, mass effect, or radiation changes
FBC, CRP, U&Es (if management would change):Inflammatory response, anaemia, renal function for antimicrobial/opioid dosing
Sputum microscopy/culture (selected cases):Likely infective organism and sensitivities when recurrent or severe infection suspected
CT thorax (± contrast) in secondary care:Endobronchial disease, lymphangitis carcinomatosa, mediastinal compression, fistula, metastatic burden
V/Q scan or CTPA when PE suspected and appropriate:Perfusion defects or embolus where diagnosis would alter treatment goals
Swallow assessment (speech and language therapy):Aspiration risk and safer fluid/food strategies
Management
Lifestyle Modifications
- Clarify goals of care and whether investigations/treatments are proportionate to prognosis and patient preference
- Optimize positioning (upright), breathing pacing, and handheld fan if dyspnoea co-exists
- Hydration and humidification to reduce tenacious secretions
- Physiotherapy techniques for sputum clearance when cough is weak but secretion burden is high
- Trigger reduction (smoke, reflux-provoking meals, environmental irritants)
- Medication review and stop/switch cough-provoking drugs where feasible (e. g, ACE inhibitor)
Pharmacological Treatment
Opioid antitussives (refractory distressing dry cough)
- Morphine sulfate oral solution 2.5 mg every 4 hours PRN, titrate cautiously
- Modified-release morphine sulfate 5 mg twice daily, increase to 10 mg twice daily if needed/tolerated
- Codeine phosphate 15-30 mg orally every 4-6 hours (max 240 mg/day)
Use lowest effective dose; monitor sedation, constipation, nausea, and respiratory depression. Reduce dose in renal impairment (especially morphine metabolite accumulation). Avoid codeine in severe respiratory depression; caution in frailty and concomitant sedatives.
Treat reversible airway inflammation/oedema from tumour compression
- Dexamethasone 4-8 mg orally once daily (often morning dose), then review and taper to lowest effective dose
Particularly useful when airway/mediastinal inflammation contributes. Safety: hyperglycaemia, proximal myopathy, mood change/psychosis, GI irritation, infection risk; consider gastroprotection in high-risk patients.
Bronchospasm-directed therapy
- Salbutamol inhaler 100-200 micrograms PRN via spacer
- Ipratropium bromide inhaler 20-40 micrograms four times daily
- Prednisolone 30-40 mg orally once daily short course if acute asthma/COPD-type exacerbation
Only when wheeze/obstructive physiology present. Check inhaler technique and ability to use device. Antimuscarinics may worsen urinary retention or angle-closure glaucoma.
Antimicrobial therapy for suspected bacterial chest infection (goal-directed)
- Amoxicillin 500 mg to 1 g orally three times daily for 5 days
- Doxycycline 200 mg on day 1 then 100 mg once daily (typically 5 days)
- Clarithromycin 500 mg orally twice daily for 5 days if penicillin allergy/atypical cover needed
Choose according to local antimicrobial guidance, allergy history, and treatment goals. Review for QT-prolonging interactions (macrolides), C. difficile risk, and renal/hepatic dosing.
Reflux/aspiration-associated cough
- Omeprazole 20 mg once daily (increase if persistent reflux symptoms)
- Alginate (e. g, sodium alginate preparations) after meals and at bedtime
Most useful with clear reflux phenotype. Reassess indication regularly; long-term PPI risks include hypomagnesaemia, fractures, and enteric infection.
Excessive respiratory secretions/bronchorrhoea
- Glycopyrronium bromide 200 micrograms subcutaneously every 4 hours PRN or via continuous infusion 0.6-1.2 mg/24 h
- Hyoscine butylbromide 20 mg subcutaneously every 4 hours PRN or continuous infusion 60-120 mg/24 h
Use when secretion load drives cough and distress. Anticholinergic adverse effects: dry mouth, confusion (less with glycopyrronium), urinary retention, tachycardia; caution in glaucoma and bowel obstruction.
Surgical / Interventional
- Therapeutic pleural aspiration or indwelling pleural catheter for recurrent malignant pleural effusion
- Endobronchial interventions (stent, debulking, laser) for central airway obstruction in selected patients
- Palliative thoracic radiotherapy for cough from local tumour mass effect or haemoptysis
- Management of tracheo-oesophageal fistula (stenting) where consistent with goals of care
Complications
- Sleep disruption, exhaustion, and reduced quality of life
- Social withdrawal, embarrassment, and impaired communication
- Stress urinary incontinence
- Haemodynamic effects (arrhythmia, hypotension)
- Epistaxis, conjunctival haemorrhage, and haemoptysis
- Vomiting and poor oral intake
- Musculoskeletal pain, rib fracture, or hernia
- Cough syncope and headache
- Pneumothorax (rare but serious)
Prognosis
Prognosis depends mainly on the underlying disease trajectory, reversibility of contributing causes, and treatment burden tolerance. Cough often improves if a reversible contributor (infection, effusion, bronchospasm, reflux, medication trigger) is treated, but persistent cough is common in advanced thoracic malignancy and may require ongoing symptom-focused opioid and supportive management. Early goal-setting and regular review usually improve comfort even when cure is not possible.
Sources & References
💊BNF Drug References(21)
- Baclofen[management.pharmacological]
- Co-danthramer[management.pharmacological]
- Co-danthrusate[management.pharmacological]
- Dexamethasone[management.pharmacological]
- Diazepam[management.pharmacological]
- Dipipanone hydrochloride with cyclizine[cautions]
- Domperidone[management.pharmacological]
- Glycopyrronium bromide[management.pharmacological]
- Haloperidol[management.pharmacological]
- Hyoscine butylbromide[management.pharmacological]
- Hyoscine hydrobromide[management.pharmacological]
- Levomepromazine[management.pharmacological]
- Loperamide hydrochloride[management.pharmacological]
- Methadone hydrochloride[management.pharmacological]
- Metoclopramide hydrochloride[management.pharmacological]
- Midazolam[management.pharmacological]
- Morphine[management.pharmacological]
- Naloxone hydrochloride[cautions]
- Nifedipine[management.pharmacological]
- Octreotide[management.pharmacological]
- Oxycodone hydrochloride[management.pharmacological]
✅NICE Guidelines(1)
- Palliative care - cough[overview]
📖Textbook References(20)
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1778)[context]
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1786)[context]
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1784)[context]
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1788)[context]
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1777)[context]
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1790, 1791)[context]
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1827)[context]
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1788)[context]
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1781)[context]
- David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1778, 1779)[context]
- [Oxford Medical Handbooks] Ian Wilkinson, Tim Raine, Kate Wiles, Anna Goodhart, Catriona Ha - Oxford Handbook of Clinical Medicine (2017, Oxford University Press) - libgen.li.pdf(pp. 539, 540)[context]
- [Oxford Medical Handbooks] Ian Wilkinson, Tim Raine, Kate Wiles, Anna Goodhart, Catriona Ha - Oxford Handbook of Clinical Medicine (2017, Oxford University Press) - libgen.li.pdf(pp. 548, 549)[context]
- [Oxford Medical Handbooks] Ian Wilkinson, Tim Raine, Kate Wiles, Anna Goodhart, Catriona Ha - Oxford Handbook of Clinical Medicine (2017, Oxford University Press) - libgen.li.pdf(pp. 552)[context]
- [Oxford Medical Handbooks] Ian Wilkinson, Tim Raine, Kate Wiles, Anna Goodhart, Catriona Ha - Oxford Handbook of Clinical Medicine (2017, Oxford University Press) - libgen.li.pdf(pp. 551, 552)[context]
- [Oxford Medical Handbooks] Ian Wilkinson, Tim Raine, Kate Wiles, Anna Goodhart, Catriona Ha - Oxford Handbook of Clinical Medicine (2017, Oxford University Press) - libgen.li.pdf(pp. 550, 551)[context]
- [Oxford Medical Handbooks] Ian Wilkinson, Tim Raine, Kate Wiles, Anna Goodhart, Catriona Ha - Oxford Handbook of Clinical Medicine (2017, Oxford University Press) - libgen.li.pdf(pp. 547)[context]
- [Oxford Medical Handbooks] Ian Wilkinson, Tim Raine, Kate Wiles, Anna Goodhart, Catriona Ha - Oxford Handbook of Clinical Medicine (2017, Oxford University Press) - libgen.li.pdf(pp. 875)[context]
- [Oxford Medical Handbooks] Ian Wilkinson, Tim Raine, Kate Wiles, Anna Goodhart, Catriona Ha - Oxford Handbook of Clinical Medicine (2017, Oxford University Press) - libgen.li.pdf(pp. 7, 8)[context]
- [Oxford Medical Handbooks] Ian Wilkinson, Tim Raine, Kate Wiles, Anna Goodhart, Catriona Ha - Oxford Handbook of Clinical Medicine (2017, Oxford University Press) - libgen.li.pdf(pp. 7, 8, 9)[context]
- [Oxford Medical Handbooks] Ian Wilkinson, Tim Raine, Kate Wiles, Anna Goodhart, Catriona Ha - Oxford Handbook of Clinical Medicine (2017, Oxford University Press) - libgen.li.pdf(pp. 549, 550)[context]